In addition, several investigators have demonstrated the correlation between the immunohistochemical overexpression of p53 in primary gastric cancer and the resistance to cisplatin-contained regimens (Hamada et al, 1996; Cascinu et al, 1998; Nakata et al, 1998). This evidence concerns the gene TP53 and gastric cancer.